- Home
- SONM vs HOOK Comparison
SONM vs HOOK Comparison
Compare SONM & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONM
- HOOK
- Stock Information
- Founded
- SONM 1999
- HOOK 2011
- Country
- SONM United States
- HOOK United States
- Employees
- SONM N/A
- HOOK N/A
- Industry
- SONM Telecommunications Equipment
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- SONM Telecommunications
- HOOK Health Care
- Exchange
- SONM Nasdaq
- HOOK Nasdaq
- Market Cap
- SONM 10.2M
- HOOK 9.3M
- IPO Year
- SONM 2019
- HOOK 2019
- Fundamental
- Price
- SONM $1.01
- HOOK $1.50
- Analyst Decision
- SONM
- HOOK Buy
- Analyst Count
- SONM 0
- HOOK 4
- Target Price
- SONM N/A
- HOOK $10.67
- AVG Volume (30 Days)
- SONM 264.7K
- HOOK 169.9K
- Earning Date
- SONM 05-12-2025
- HOOK 06-17-2025
- Dividend Yield
- SONM N/A
- HOOK N/A
- EPS Growth
- SONM N/A
- HOOK N/A
- EPS
- SONM N/A
- HOOK N/A
- Revenue
- SONM $58,243,000.00
- HOOK $9,351,000.00
- Revenue This Year
- SONM $127.68
- HOOK N/A
- Revenue Next Year
- SONM N/A
- HOOK N/A
- P/E Ratio
- SONM N/A
- HOOK N/A
- Revenue Growth
- SONM N/A
- HOOK N/A
- 52 Week Low
- SONM $0.85
- HOOK $0.72
- 52 Week High
- SONM $10.70
- HOOK $8.50
- Technical
- Relative Strength Index (RSI)
- SONM 38.94
- HOOK 55.40
- Support Level
- SONM $0.94
- HOOK $1.51
- Resistance Level
- SONM $1.04
- HOOK $1.65
- Average True Range (ATR)
- SONM 0.09
- HOOK 0.14
- MACD
- SONM 0.03
- HOOK -0.02
- Stochastic Oscillator
- SONM 51.72
- HOOK 34.78
About SONM Sonim Technologies Inc.
Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.